Published in final edited form as:

Am J Ophthalmol. 2014 September ; 158(3): 597–604.e1. doi:10.1016/j.ajo.2014.05.021.

Bleb Revision for Resolution of Hypotony Maculopathy Following Primary Trabeculectomy

ELENA BITRIAN,

Elena Bitrian is currently affiliated with the Department of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, Minnesota.

BRIAN J. SONG, and

Brian J. Song is currently affiliated with the Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

JOSEPH CAPRIOLI

Inquiries to Joseph Caprioli, Jules Stein Eye Institute, 100 Stein Plaza, Los Angeles, CA 90025; caprioli@ucla.edu

Jules Stein Eye Institute, Department of Ophthalmology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California.

Abstract

PURPOSE—To describe a surgical method of bleb revision for hypotony maculopathy, to evaluate its long-term efficacy, and to define the relationship between the duration of hypotony maculopathy and visual acuity (VA) outcomes.

DESIGN—Noncomparative retrospective case series.

METHODS—Medical records of 33 patients with hypotony maculopathy who underwent primary bleb revision between June 1999 and September 2012 by a single surgeon at an academic medical center were reviewed. Hypotony maculopathy was characterized by the presence of a decrease in VA, retinal striae, and macular edema in the setting of decreased intraocular pressure (IOP) after glaucoma filtering surgery. The main outcome measure was final logMAR VA after bleb revision at 6 and 12 months.

RESULTS—Thirty-three eyes of 33 patients were followed for 4.68 ± 3.56 years (range 0.55–12.69 years). Mean duration of hypotony maculopathy was 4.98 ± 8.93 months. LogMAR VA improved from 0.78 ± 0.40 at baseline to 0.34 ± 0.34 ($P < .001$) 6 months after bleb revision and to 0.45 ± 0.55 ($P < .001$) 12 months after bleb revision. Spearman rank coefficient (r_s) correlating duration of hypotony and BCVA at both 6 and 12 months was significant ($P = .015$ and $r_s = 0.426$, $P = .028$ and $r_s = 0.416$, respectively). Mean IOP increased from 3.51 ± 2.27 mm Hg to $12.06 \pm$

© 2014 by Elsevier Inc. All rights reserved.

ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST. Elena Bitrian has no financial disclosures.

Contributions of authors: conception and design of the study (E.B., J.C.); conduct of the study (E.B., B.J.S.); collection (E.B., B.J.S.), management (E.B., B.J.S., J.C.), analysis (E.B., B.J.S.), and interpretation of the data (E.B., B.J.S., J.C.); preparation (E.B., B.J.S.), review, or approval of the manuscript (E.B., B.J.S., J.C.).

4.06 mm Hg ($P < .001$) at 12 months. Fifty-two percent were on no antiglaucoma medications at last follow-up. Five eyes (15%) required a second bleb revision to correct persistent hypotony maculopathy.

CONCLUSION—Surgical repair for hypotony maculopathy provided a significant improvement in VA at 6 and 12 months. Surgical bleb revision is associated with good long-term control of IOP and improved VA in eyes with hypotony maculopathy after previous glaucoma filtering surgery.

HYPOTONY MACULOPATHY IS A COMPLICATION of glaucoma filtration surgery that occurs in 1.3%–20% of eyes having undergone trabeculectomy with mitomycin C (MMC).^{1–6} The clinical findings were first described by Dellaporta in 1954 as “creasing of retina in hypotonia,”⁷ but the actual term for hypotony maculopathy was not coined until 1972 by Gass to emphasize the etiology of vision loss in the setting of chorioretinal folds.⁸ The condition is characterized by a decrease in visual acuity caused by macular folds, retinal edema, papilledema, and vascular tortuosity.⁹ Structurally, it has been postulated that low intraocular pressure (IOP) causes thickening of the perifoveal choroid and sclera, which causes the perifoveal and foveal retina to become displaced centrally, giving the appearance of radial folds clinically.⁸ Over time, these changes can cause photoreceptor damage, which can limit recovery of visual function even after normal IOP has been restored.¹⁰

Statistically, hypotony can be defined as an intraocular pressure of less than 6.5 mm Hg, which is greater than 3 standard deviations below the mean IOP.⁸ Clinically, hypotony has been described as a low pressure in an individual eye leading to pathologic functional and structural changes.¹¹ In the setting of glaucoma surgery, hypotony is oftentimes the result of overfiltration or excessive aqueous outflow.¹² It is well established that the use of antifibrotic agents (particularly MMC) at the time of glaucoma surgery increases the probability of a successful outcome.^{2,13–15} However, the use of such agents as an adjunct to trabeculectomy has also been associated with an increased incidence of ocular hypotony.^{1,9,16} In addition, some studies have shown that the frequency of hypotony maculopathy occurs more commonly as the dose or duration of adjunctive intraoperative MMC is increased.^{6,16} Other risk factors that have been associated with the development of hypotony maculopathy include male sex, younger age, myopia, and preoperative use of carbonic anhydrase inhibitors.^{9,17,18}

When left untreated, hypotony maculopathy can have long-term visual consequences.¹⁸ Proposed treatments for postsurgical hypotony maculopathy are centered on methods to decrease aqueous outflow and to raise IOP to functional levels. Some of the more conservative measures of treatment include pressure patching and the application of trichloroacetic acid or cryotherapy directly to the bleb.^{19,20} Placement of an oversized bandage contact lens has also been shown in 1 study to be helpful for early postoperative hypotony.²¹ Injection of autologous blood into or around the bleb is reported to produce more variable results;^{22–27} however, complications have been reported with this procedure.^{28–31} A variety of surgical approaches have been proposed, including resuturing of the scleral flap, patch grafting with donor pericardium or sclera, placement of compression sutures, and transconjunctival suturing of the scleral flap.^{6,32–38}

We propose that surgical bleb revision is a safe and effective primary method of treating hypotony maculopathy in the setting of overfiltration from trabeculectomy. The purpose of this study is to evaluate the results of surgical bleb revision in those patients with post-trabeculectomy hypotony maculopathy by evaluating changes in visual acuity (VA) and IOP, and to correlate these results with the duration of hypotony maculopathy.

METHODS

APPROVAL FROM THE INSTITUTIONAL REVIEW BOARD OF the University of California, Los Angeles was obtained to conduct this noncomparative, retrospective case series. The medical records of all patients who underwent bleb revision surgery by a single surgeon (J.C.) at the Jules Stein Eye Institute between October 11, 1999 and July 16, 2012 were identified and reviewed. Patients who had previously undergone primary trabeculectomy with adjunctive MMC and subsequently developed hypotony maculopathy in the postoperative period were included. Other inclusion criteria included age 18 years or greater and a minimum follow-up of at least 6 months following bleb revision surgery. The diagnosis of hypotony maculopathy was defined clinically according to the presence of macular folds on funduscopy in the setting of an IOP <6 mm Hg or an IOP greater than this in the presence of typical clinical features of hypotony maculopathy and a decrease of 1 or more lines in the best-corrected Snellen visual acuity. Eyes with a history of any other incisional surgery besides trabeculectomy or cataract surgery, prior to the onset of hypotony maculopathy, were excluded.

SURGICAL PROCEDURE

Anesthesia for all patients at the time of surgery consisted of a peribulbar block of 2% lidocaine. A 3 mL injection was delivered to the inferotemporal orbit with a 23 gauge Atkinson needle. All blocks were performed under monitored anesthesia care in the presence of an anesthesiologist. Topical tetracaine 0.5% eye drops were used to supplement the block as needed during the surgery.

Bleb revision involved sharp dissection and excision of thin or leaky conjunctiva and adjacent Tenon capsule along the outer aspect of the bleb with Westcott scissors. The scleral flap was resutured with 1 or more interrupted 10-0 nylon sutures, when the strength of the tissue permitted. In some cases, a pericardial patch graft or a horizontal mattress compression suture was used to provide additional resistance to aqueous outflow if resuturing of the scleral flap alone was found to be insufficient for this purpose. Finally, the conjunctiva was mobilized by freeing its attachments to the sclera and superior rectus muscle, advanced, and reattached to the limbus with a 9-0 monofilament polyglactin suture on a tapered noncutting needle. These steps are illustrated in Figure 1.

When deemed necessary by the surgeon, drainage of suprachoroidal fluid was performed in the presence of an anterior chamber maintainer by creating a conjunctival peritomy in the area of the choroidal effusion. A scleral cutdown was then performed approximately 3 mm posterior to the limbus. After initial drainage of suprachoroidal fluid, a Barraquer sweep was inserted into the suprachoroidal space parallel to the limbus to access and remove any other existing pockets of fluid. The scleral wound was then closed with a 9-0 polyglactin suture.

MAIN OUTCOMES

Demographic data, including age, race, sex, ocular history, and glaucoma subtype, were collected for all patients. All visual acuity was converted to logMAR visual acuity from the recorded best-corrected Snellen visual acuity (BCVA). The BCVA at the time of hypotony maculopathy diagnosis was compared with the BCVA after bleb revision at 6 and 12 months. IOP measurements were also collected at the same time points. Duration of hypotony from the time of diagnosis until bleb revision was recorded, in addition to any complications after bleb revision surgery, including the need for additional surgery. Other variables that were analyzed include surgical technique at the time of bleb revision and the number of glaucoma medications needed for adequate IOP control at final follow-up. The relationship between logMAR BCVA at 12 months as a function of both duration of hypotony maculopathy and preoperative IOP was also plotted. Successful resolution of hypotony maculopathy was not defined by IOP criteria alone but was also defined by improvement of BCVA and macular abnormalities. Failure was defined as IOP <5 mm Hg, decreased visual acuity, persistent macular striae or macular edema, need for a second bleb revision surgery, or need for additional glaucoma surgery for IOP reduction.

STATISTICAL ANALYSIS

Statistical analysis was performed with a paired-samples *t* test to compare logMAR BCVA and IOP preoperatively and postoperatively. Long-term outcomes were plotted on a Kaplan-Meier survival curve according to predefined criteria for failure. Specifically, postoperative failure was defined as an IOP of less than 5 mm Hg, a decrease in BCVA from baseline, persistence of macular striae or edema after revision, the need for a second bleb revision, or the need for additional glaucoma surgery to achieve adequate IOP control. The Spearman rank correlation coefficient (r_s) was used to determine the correlation between duration of hypotony maculopathy and logMAR BCVA at 6 and 12 months. All data are presented as the mean $\pm$ standard deviation unless otherwise indicated. A *P* value of <.05 was considered statistically significant for the purpose of our analysis.

RESULTS

DEMOGRAPHICS AND CLINICAL CHARACTERISTICS

A total of 126 charts of patients who underwent bleb revision were reviewed. Thirty-three eyes of 33 patients met criteria for trabeculectomy-induced hypotony maculopathy and were included in this study. Bleb revision in the remaining 93 patients was performed for other reasons, such as the presence of a bleb leak in the absence of hypotony maculopathy, glaucoma progression requiring revision of an existing bleb to achieve a further reduction in IOP, bleb dysesthesia, or bleb failure leading to inadequate IOP control. Demographic and clinical characteristics of the study patients are summarized in the Table. The average age of the study population was 63.12 ± 13.3 years (range 43–93 years). Sixteen patients were male and 17 were female. Demographic and clinical characteristics, including race and glaucoma diagnosis, are summarized in the Table.

All study patients had previously undergone an initial trabeculectomy with MMC. Concentration of MMC used was available for 16 patients and ranged from 0.2 mg/mL to

0.3 mg/mL for 1 minute in those patients. Of these, 14 patients received MMC at a concentration of 0.3 mg/mL at the time of trabeculectomy, 1 received 0.25 mg/mL, and 1 received 0.2 mg/mL. These data were not available for the remaining 17 patients who had their initial trabeculectomy done elsewhere.

The mean time between the diagnosis of hypotony maculopathy and surgical revision was 4.98 ± 8.93 months (range 3 days–4 years). Prior to bleb revision surgery, all patients (100%) had macular striae and 5 (15%) had accompanying choroidal effusions visible on indirect ophthalmoscopy. Eight patients (24%) had macular edema at the time of diagnosis. A typical example of optical coherence tomography (OCT) findings is shown in Figure 2 for a study patient before and after bleb revision.

SURGICAL TECHNIQUE

All 33 patients underwent bleb revision surgery for hypotony maculopathy as described above in the Methods section. All patients underwent resuturing of the scleral flap with accompanying conjunctival advancement following resection of any friable or leaking conjunctival tissue. Nine patients (27%) required a pericardial patch graft to provide additional resistance to aqueous flow. Concomitant choroidal drainage was performed in 1 patient (3%). A compression suture was placed in 11 patients (33%) to further secure the scleral flap.

OUTCOMES

Patients were followed for a total of 4.68 ± 3.56 years (range 0.55–12.69 years) from the time of bleb revision surgery to final follow-up. Twenty-nine patients (88%) experienced improvement of BCVA following bleb revision, and of these, 28 patients (85%) experienced an improvement of -0.2 or more in logMAR BCVA. Mean logMAR BCVA prior to bleb revision was 0.78 ± 0.40 (range 0.2–2.0). Mean logMAR BCVA was 0.34 ± 0.34 (range 0–2.0) at 6 months after bleb revision and 0.45 ± 0.55 (range 0–2.0) 12 months after bleb revision. The change in mean BCVA at both 6 months and 12 months was found to be statistically significant, with $P < .001$ at both 6 months and 12 months when compared to the preoperative BCVA.

The mean preoperative IOP before bleb revision was 3.51 ± 2.27 mm Hg (range 0.5–10 mm Hg). Mean IOP at 6 and 12 months post bleb revision were 11.03 ± 4.73 mm Hg (range 3–20 mm Hg) and 12.06 ± 4.06 mm Hg (range 3–21 mm Hg), respectively. Mean IOP at 6 and 12 months was significantly higher than preoperative IOP, with $P < .001$ at both time points. Thirty-one out of 33 patients (94%) had a sustained increase in IOP at 12 months. Figure 3 demonstrates these BCVA and IOP results graphically.

Seventeen of the 33 study patients (52%) did not require topical glaucoma medications at final follow-up. Nine patients (27%) required 2 or more topical glaucoma medications to achieve adequate IOP control at their last follow-up visit.

LogMAR VA at 12 months was also plotted as a function of hypotony duration as well as preoperative IOP. These results are shown graphically in Figures 4 and 5. Duration of hypotony maculopathy vs change in logMAR VA was also plotted (Figure 6).

The Spearman rank correlation coefficient between duration of hypotony maculopathy and logMAR BCVA at both 6 months and 12 months was 0.43 and 0.42, respectively. These values were statistically significant at both time points ($P = .015$ at 6 months and $P = .028$ at 12 months).

COMPLICATIONS AND POSTOPERATIVE COURSE

There were no cases of endophthalmitis, blebitis, or suprachoroidal hemorrhage among the study patients. Four patients (12%) experienced no improvement in visual acuity. A second bleb revision was required in 5 patients (15%). None of the 33 patients required additional glaucoma surgery to decrease IOP during the follow-up period. Sixteen patients (48.5%) eventually required topical glaucoma medications to maintain adequate IOP control. A Kaplan-Meier survival curve of long-term bleb revision outcomes is shown in Figure 7.

DISCUSSION

in this retrospective case series, we characterized the visual acuity and IOP outcomes of patients with trabeculectomy-induced hypotony maculopathy who subsequently underwent bleb revision. This study represents the largest series of bleb revision outcomes for trabeculectomy-induced hypotony maculopathy published to date, with a mean follow-up of 4.7 years.

After bleb revision, 29 out of 33 patients (88%) experienced improvement in BCVA, and of these, 28 patients (97%) had an improvement of logMAR BCVA of -0.2 or more. Most subjects (94%) experienced a sustained increase in IOP after bleb revision, and over half (52%) did not require glaucoma medications at the end of follow-up to maintain therapeutic IOPs. A second bleb revision surgery was required in 5 cases (15%) to achieve a target IOP at which hypotony maculopathy would not recur. None of the study patients required a second glaucoma surgery to treat elevated IOP after bleb revision.

In general, the highest IOP during the follow-up period was measured on postoperative day 1. We believe that this is caused by dysfunction of the natural outflow pathways that are seeing essentially none of the aqueous outflow during the period of overfiltration. When outflow through the trabeculectomy is suddenly inhibited by surgical revision of the bleb, there is a transient rise in IOP during the immediate postoperative period until a new physiologic equilibrium, with some contribution from normal outflow pathways, is established. Furthermore, this spike in IOP may be helpful in expediting the resolution of any preexisting serous choroidal detachments when they are present as a result of hypotony. In our series, IOP appeared to return to physiologic levels in most cases by postoperative week 1, with most patients reaching stable IOPs by postoperative month 3.

Hypotony maculopathy is a complication of glaucoma surgery that has become more common since the introduction of intraoperative antifibrotic agents.^{5,6,16} Though the diagnosis is made clinically, the increased availability and improvements in OCT technology have helped to identify clinically ambiguous cases of hypotony maculopathy and to better monitor treatment.^{39,40} Overfiltration, bleb leak, or reduced aqueous humor production attributable to postoperative inflammation are the most common causes of

hypotony after trabeculectomy. When left untreated, hypotony can lead to maculopathy, which manifests clinically as macular and foveal striae, choroidal folds, disc edema, macular edema, and tortuosity of the retinal vessels.

A variety of treatments have been proposed for the treatment of hypotony caused by overfiltration after trabeculectomy. Nonsurgical measures reported in the literature include the use of bandage contact lenses, autologous blood injection, argon or neodymium–yttrium–aluminum–garnet laser, and trichloroacetic acid surface abrasion.^{19–31} Cataract surgery and amniotic membrane grafting have also been proposed as alternatives to surgical bleb revision.^{41–44}

A variety of techniques for surgical bleb revision have been reported for treating overfiltering blebs. Some authors have proposed leaving the avascular bleb tissue intact and pulling a new conjunctival flap over it to act as a barrier to outflow.⁴⁵ Others recommend excision of the old bleb, as this allows the surgeon to directly visualize and reinforce the scleral flap with additional sutures or a pericardial patch graft as needed.⁴⁶ The use of a transconjunctival suture of the scleral flap directly through the old bleb has been shown recently to be a safe and effective surgical alternative in treating overfiltration as well.^{36,38}

When there is insufficient conjunctiva to create a new bleb, either a free conjunctival graft or a conjunctival rotation flap can be used to provide necessary coverage.⁴⁷ Alternatively, a large, forniceal relaxing incision can be made to mobilize the conjunctiva anteriorly to cover the exposed surgical site.³⁷ Our own experience has been that these techniques are rarely necessary if a careful separation and mobilization of conjunctiva and Tenon capsule is performed at the time of bleb revision.

Only patients who developed hypotony maculopathy after primary trabeculectomy were included in this study. Based on our clinical experience, correction of overfiltration and hypotony maculopathy in eyes that have undergone repeated trabeculectomies are oftentimes less amenable to the techniques described here as a result of degradation of the surrounding conjunctiva and sclera over time. As a result, such eyes are less likely to develop a functional filtration bleb over time and were thus excluded from our analysis.

Many studies have reported the outcomes of various methods of bleb revision surgery; however, only a few studies have examined the outcomes of bleb revision specifically for hypotony maculopathy. Cohen and associates previously reported results of resuturing the scleral flap and found that 6 of 9 eyes recovered visual acuity to within 1 Snellen line of the initial level.³³ The duration of hypotony in their study ranged from 0.5 to 17.5 months, and the investigators found no correlation between hypotony duration and final visual outcome.³³ A similar study of 14 patients also reported no correlation between visual recovery and duration of hypotony and found that 12 of 14 patients regained an average best-corrected vision of 3.08 lines.¹ In contrast to these studies, we found a significant correlation between duration of hypotony maculopathy and BCVA at both 6 and 12 months. In general, the greatest improvements in BCVA were seen in those who underwent bleb revision following a shorter duration of hypotony maculopathy (Figure 6), although there were 2 patients in our series who experienced an improvement in logMAR VA of 0.2 or

more after greater than 10 months of hypotony maculopathy. It is likely that long-standing macular striae and edema leads to foveal photoreceptor dysfunction in a similar fashion as described for chronic cystoid macular edema, which ultimately limits the potential for visual recovery.⁴⁸ A third study of 177 eyes that underwent bleb revision for 1 of 3 different indications (hypotony without leak, bleb leak, and bleb dysesthesia), by Radhakrishnan and associates, showed that revision surgery provided successful resolution of bleb-related complications, with most patients maintaining good IOP control thereafter.⁴⁹ However, the relationship between duration of hypotony and final visual outcome was not evaluated in their study.

To date, this study represents the largest reported series of patients who have undergone bleb revision for post-trabeculectomy hypotony maculopathy. Although multiple methods exist for treating trabeculectomy-induced hypotony maculopathy, surgical bleb revision with the techniques described here results in sustained improvements of BCVA and IOP with relatively few complications. Though it is recommended that postoperative hypotony be corrected in a timely fashion whenever possible, the majority of patients in this study experienced some recovery of vision despite a mean duration of hypotony of nearly 5 months. However, further studies are needed to determine the duration of hypotony for which treatment is still effective in restoring visual function, should the surgeon elect to attempt more conservative measures first. In conclusion, surgical bleb revision in patients with trabeculectomy-induced hypotony maculopathy is associated with long-term improvement of both BCVA and IOP.

Acknowledgments

Brian J. Song currently receives support by grant K12 EY016335-08 through an institutional mentored K12 clinician-scientist award from the National Institutes of Health, Bethesda, Maryland. He has also received funding through a Mentoring for the Advancement of Physician Scientists Award from the American Glaucoma Society (San Francisco, California). Joseph Caprioli receives support from grant R01-EY-018644 through the National Institutes of Health, Bethesda, Maryland. He has also received grant support from Alcon Inc. (Forth Worth, Texas), Allergan Inc. (Irvine, California), and New World Medical Inc. (Rancho Cucamonga, California). He is a consultant for Allergan Inc., Irvine, California. This research was supported by an unrestricted departmental grant from Research to Prevent Blindness, Inc. (New York, New York).

REFERENCES

1. Bashford KP, Shafranov G, Shields MB. Bleb revision for hypotony maculopathy after trabeculectomy. *J Glaucoma*. 2004; 13(3):256–260. [PubMed: 15118473]
2. Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R. Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up. *Ophthalmology*. 2002; 109(7):1336–1341. [PubMed: 12093659]
3. Tsai JC, Chang HW, Kao CN, Lai IC, Teng MC. Trabeculectomy with mitomycin C versus trabeculectomy alone for juvenile primary open-angle glaucoma. *Ophthalmologica*. 2003; 217(1): 24–30. [PubMed: 12566869]
4. Suñer JJ, Greenfield DS, Miller MP, Nicolela MT, Palmberg PF. Hypotony maculopathy after filtering surgery with mitomycin C. Incidence and treatment. *Ophthalmology*. 1997; 104(2):207–214.
5. Costa VP, Wilson RP, Moster MR, Schmidt CM, Gandham S. Hypotony maculopathy following the use of topical mitomycin C in glaucomafiltrationsurgery. *OphthalmicSurg*. 1993; 24(6):389–394.

6. Shields MB, Scroggs MW, Sloop CM, Simmons RB. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. *Am J Ophthalmol.* 1993; 116(6):673–683. [PubMed: 8250068]
7. Dellaporta A. Creasing of retina in hypotonia. *Klin Monbl Augenheilkd Augenarztl Fortbild.* 1954; 125(6):872–878.
8. Gass, JD. Hypotony maculopathy. In: Bellows, JG., editor. *Contemporary Ophthalmology: Honoring Sir Stewart Duke-Elder.* Williams and Wilkins; Baltimore: 1972. p. 343-366.
9. Costa VP, Arcieri ES. Hypotony maculopathy. *Acta Ophthalmol Scand.* 2007; 85(6):586–597. [PubMed: 17542978]
10. Oyakhire JO, Moroi SE. Clinical and anatomical reversal of long-term hypotony maculopathy. *Am J Ophthalmol.* 2004; 137(5):953–955. [PubMed: 15126172]
11. Schubert HD. Postsurgical hypotony: Relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. *Surv Ophthalmol.* 1996; 41(2):97–125. [PubMed: 8890437]
12. Lin RC, Mieler WF. Management of retinal complications following glaucoma surgery. *Retinal Physician.* 2007; 4(1):33–35. 44.
13. Scott IU, Greenfield DS, Schiffman J, et al. Outcomes of primary trabeculectomy with the use of adjunctive mitomycin. *Arch Ophthalmol.* 1998; 116(3):286–291. [PubMed: 9514480]
14. Smith MF, Doyle JW, Nguyen QH, Sherwood MB. Results of intra-operative 5-fluorouracil or lower dose mitomycin-C administration on initial trabeculectomy surgery. *J Glaucoma.* 1997; 6(2):104–110. [PubMed: 9098818]
15. Fontana H, Nouri-Mahdavi K, Lumba J, Ralli M, Caprioli J. Trabeculectomy with mitomycin C: outcomes and risk factors for failure in phakic open-angle glaucoma. *Ophthalmology.* 2006; 113(6):930–936. [PubMed: 16647135]
16. Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. *Am J Ophthalmol.* 1993; 116(3):314–326. [PubMed: 8357056]
17. Fannin LA, Schiffman JC, Budenz DL. Risk factors for hypotony maculopathy. *Ophthalmology.* 2003; 110(6):1185–1191. [PubMed: 12799246]
18. Seah SK, Prata JA Jr, Minckler DS, Baerveldt G, Lee PP, Heuer DK. Hypotony following trabeculectomy. *J Glaucoma.* 1995; 4(2):73–79. [PubMed: 19920649]
19. Allingham, RR.; Damji, KF.; Freedman, S.; Moroi, SE.; Rhee, DJ., editors. *Shields Textbook of Glaucoma.* 6th ed. Lippincott Williams and Wilkins; Philadelphia: 2011. p. 501-523.
20. Gehring JR, Ciccarelli EC. Trichloroacetic acid treatment of filtering blebs following cataract extraction. *Am J Ophthalmol.* 1972; 74(4):622–624. [PubMed: 5075130]
21. Smith MF, Doyle JW. Use of oversized bandage soft contact lenses in the management of early hypotony following filtration surgery. *Ophthalmic Surg Lasers.* 1996; 27(6):417–421. [PubMed: 8782252]
22. Wise JB. Treatment of chronic postfiltration hypotony by intrableb injection of autologous blood. *Arch Ophthalmol.* 1993; 111(6):827–830. [PubMed: 8512485]
23. Leen MM, Moster MR, Katz LJ, Terebuh AK, Schmidt CM, Spaeth GL. Management of overfiltering and leaking blebs with autologous blood injection. *Arch Ophthalmol.* 1995; 113(8): 1050–1055. [PubMed: 7639657]
24. Chen PP, Palmberg PF, Culbertson WW, Davis JL. Management of overfiltering and leaking blebs with autologous blood injection. *Arch Ophthalmol.* 1996; 114(5):633–634. [PubMed: 8619785]
25. Okada K, Tsukamoto H, Masumoto M, et al. Autologous blood injection for marked overfiltration early after trabeculectomy with mitomycin C. *Acta Ophthalmol Scand.* 2001; 79(3):305–308. [PubMed: 11401645]
26. Choudhri SA, Herndon LW, Damji KF, Allingham RR, Shields MB. Efficacy of autologous blood injection for treating overfiltering or leaking blebs after glaucoma surgery. *Am J Ophthalmol.* 1997; 123(4):554–555. [PubMed: 9124257]
27. Burnstein A, WuDunn D, Ishii Y, Jonescu-Cuypers C, Cantor LB. Autologous blood injection for late-onset filtering bleb leak. *Am J Ophthalmol.* 2001; 132(1):36–40. [PubMed: 11438051]

28. Siegfried CJ, Grewal RK, Karalekas D, Rosenberg LF, Krupin T. Marked intraocular pressure rise complicating intrableb autologous blood injection. *Arch Ophthalmol*. 1996; 114(4):492–493. [PubMed: 8602792]
29. Ayyala RS, Urban RC Jr, Krishnamurthy MS, Mendelblatt DJ. Corneal blood staining following autologous blood injection for hypotony maculopathy. *Ophthalmic Surg Lasers*. 1997; 28(10): 866–868. [PubMed: 9336780]
30. Lu DW, Azuara-Blanco A, Katz LJ. Severe visual loss after autologous blood injection for mitomycin-C-associated hypotonous maculopathy. *Ophthalmic Surg Lasers*. 1997; 28(3):244–245. [PubMed: 9076802]
31. Flynn WJ, Rosen WJ, Campbell DG. Delayed hyphema and intravitreal blood following intrableb autologous blood injection after trabeculectomy. *Am J Ophthalmol*. 1997; 124(1):115–116. [PubMed: 9222247]
32. Chen PP, Takahashi Y, Leen MM, Bhandari A, Li Y, Mills RP. The effects of compression sutures on filtering blebs in rabbit eyes. *Ophthalmic Surg Lasers*. 1999; 30(3):216–220. [PubMed: 10100257]
33. Cohen SM, Flynn HW Jr, Palmberg PF, Gass JD, Grajewski AL, Parrish RK 2nd. Treatment of hypotony maculopathy after trabeculectomy. *Ophthalmic Surg Lasers*. 1995; 26(5):435–441. [PubMed: 8963858]
34. Haynes WL, Alward WL. Rapid visual recovery and long-term intraocular pressure control after donor sclera patch grafting for trabeculectomy-induced hypotony maculopathy. *J Glaucoma*. 1995; 4(3):200–201. [PubMed: 19920669]
35. Clune MJ, Shin DH, Olivier MM, Kupin TH. Partial-thickness sclera-patch graft in revision of trabeculectomy. *Am J Ophthalmol*. 1993; 115(6):818–820. [PubMed: 8506923]
36. Maruyama K, Shirato S. Efficacy and safety of transconjunctival sclera flap resuturing for hypotony after glaucoma filtering surgery. *Graefes Arch Clin Exp Ophthalmol*. 2008; 246(12): 1751–1756. [PubMed: 18751993]
37. O'Connor DJ, Tressler CS, Caprioli J. A surgical method to repair leaking filtering blebs. *Ophthalmic Surg*. 1992; 23(5):336–338. [PubMed: 1603534]
38. Eha J, Hoffman EM, Wahl J, Pfeiffer N. Flap suture - a simple technique for the revision of hypotony maculopathy following trabeculectomy with mitomycin C. *Graefes Arch Clin Exp Ophthalmol*. 2008; 246(6):869–874. [PubMed: 18389274]
39. Lima VC, Prata TS, Castro DP, et al. Macular changes detected by Fourier-domain optical coherence tomography in patients with hypotony without clinical maculopathy. *Acta Ophthalmol*. 2011; 89(3):e274–277. [PubMed: 19906084]
40. Goodkin ML, Grewal DS, Greenfield DS. Three-dimensional high-speed optical coherence tomography for diagnosis of hypotony maculopathy after glaucoma filtration surgery. *J Glaucoma*. 2010; 19(6):349–355. [PubMed: 19855288]
41. Sibayan SAB, Igarashi S, Kasahara N, et al. Cataract extraction as a means of treating postfiltration hypotony maculopathy. *Ophthalmic Surg Lasers*. 1997; 28(3):241–243. [PubMed: 9076801]
42. Okada H, Tawara A, Kubota T, Nagumo H. Amniotic membrane transplantation for repair of leaking glaucoma filtering blebs with scleral perforation. *Ophthalmic Surg Lasers Imaging*. 2010 <http://dx.doi.org/10.3928/15428877-20100210-17>
43. Budenz DL, Barton K, Tseng SC. Amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. *Am J Ophthalmol*. 2000; 130(5):580–588. [PubMed: 11078836]
44. Rauscher FM, Barton K, Budenz DL, Feuer WJ, Tseng SC. Long-term outcomes of amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. *Am J Ophthalmol*. 2007; 143(6):1052–1054. [PubMed: 17524779]
45. Catoira Y, Wudunn D, Cantor LB. Revision of dysfunctional filtering blebs by conjunctival advancement with bleb preservation. *Am J Ophthalmol*. 2000; 130(5):574–579. [PubMed: 11078835]
46. Tannenbaum DP, Hoffman D, Greaney MJ, Caprioli J. Outcomes of bleb excision and conjunctival advancement for leaking or hypotonous eyes after glaucoma filtering surgery. *Br J Ophthalmol*. 2004; 88(1):99–103. [PubMed: 14693784]

47. La Borwit SE, Quigley HA, Jampel HD. Bleb reduction and bleb repair after trabeculectomy. *Ophthalmology*. 2000; 107(4):712–718. [PubMed: 10768333]
48. Kurashige Y, Tsujikawa A, Murakami T, et al. Changes in visual acuity and foveal photoreceptor integrity in eyes with chronic cystoid macular edema associated with retinal vein occlusion. *Retina*. 2012; 32(4):792–798. [PubMed: 22080912]
49. Radhakrishnan S, Quigley HA, Jampel HD, et al. Outcomes of surgical bleb revision for complications of trabeculectomy. *Ophthalmology*. 2009; 116(9):1713–1718. [PubMed: 19643490]

FIGURE 1.

Steps of bleb revision surgery for hypotony maculopathy following primary trabeculectomy.

(Top left) Preoperative bleb with thin, necrotic conjunctiva. (Top middle) Resection of necrotic conjunctiva. (Top right) Resuturing of scleral flap with 10-0 nylon suture. (Bottom left) Dissection of posterior Tenon capsule. (Bottom middle) Conjunctival advancement and closure with 9-0 polyglactin. (Bottom right) Postoperative appearance of revised bleb.

FIGURE 2.

Fifty-three-year-old female patient with hypotony maculopathy following trabeculectomy with mitomycin C for primary open-angle glaucoma. Prior to bleb revision, intraocular pressure (IOP) was 3 mm Hg and visual acuity had decreased to 20/60 in the affected eye. Macular striae and edema are seen on both the three-dimensional (top row, first column) and two-dimensional (top row, second column) thickness maps on optical coherence tomography (OCT). Macular striae are also seen in a cross-section of the macular cube scan (top row, third column) with corresponding areas of mild thickening on the adjacent internal limiting membrane (ILM) - retinal pigment epithelium (RPE) thickness map in micrometers (top row, fourth column). Following bleb revision surgery, there is resolution of the macular abnormalities by postoperative month 3 with visual acuity returning to 20/20 and an IOP of 20 mm Hg (second row).

FIGURE 3.

(Top) Mean logMAR visual acuities before and after bleb revision for hypotony maculopathy. Improvement in visual acuity (VA) at both 6 and 12 months compared to preoperative levels was seen. (Bottom) Mean intraocular pressure (mm Hg) before and after bleb revision. Sustained increase of intraocular pressure (IOP) at 6 and 12 months following bleb revision surgery was observed. Error bars represent standard deviation.

FIGURE 4.

Plot of logMAR visual acuity (VA) at 12 months after surgical bleb revision for hypotony maculopathy as a function of hypotony duration (in months). The best visual acuity outcomes at 12 months were generally seen in those with a shorter duration of hypotony maculopathy.

FIGURE 5.

Plot of logMAR visual acuity (VA) at 12 months after surgical bleb revision for hypotony maculopathy as a function of preoperative intraocular pressure (mm Hg). The majority of study patients achieved good visual acuity at 12 months irrespective of preoperative intraocular pressure.

FIGURE 6.

Graph depicting the log of the duration of hypotony maculopathy in months (x-axis) vs change in logMAR visual acuity (y-axis) in patients who underwent bleb revision surgery for hypotony maculopathy. The greatest improvements in visual acuity (VA) were generally achieved in those with a shorter duration of hypotony maculopathy.

FIGURE 7.

Survival curve of bleb revision surgery in patients with hypotony maculopathy following primary trabeculectomy. Failure was defined as intraocular pressure (IOP) <5 mm Hg, decreased visual acuity, persistent macular striae or macular edema, need for a second bleb revision surgery, or need for additional glaucoma surgery for IOP reduction.

TABLE

Demographics and Clinical Characteristics of Patients who Underwent Bleb Revision Surgery for Hypotony Maculopathy Following Primary Trabeculectomy

Age (y)	63.12 ± 13.3 (range: 43–93)
Male:female ratio	16:17
Race	27 (82%) white 2 (6%) African American 1 (3%) Hispanic 3 (9%) Asian
Laterality	20 (60.6%) left eyes
Type of glaucoma	17 (52%) primary open-angle glaucoma 2 (6%) pigmentary dispersion glaucoma 2 (6%) pseudoexfoliative glaucoma 5 (15%) normal tension glaucoma 2 (6%) chronic angle closure glaucoma 1 (3%) steroid-induced glaucoma 2 (6%) uveitic glaucoma 1 (3%) angle recession glaucoma
Lens status	15 (45.5%) phakic 18 (55.5%) pseudophakic
Macula striae	33 (100%)
Choroidal effusion	5 (15%)
Macular edema	8 (24%)
Duration of hypotony	4.98 ± 8.93 months (3 days–4 years)